Enveric Biosciences responds to FDA final guidance on psychedelic drug development

Enveric Biosciences (NASDAQ: ENVB) responded to the U.S. Food and Drug Administration's release of finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics, stating the guidance supports the design rationale behind its lead drug candidate, EB-003.

The FDA guidance identifies several clinical challenges associated with hallucinogenic compounds, including functional unblinding in trials, the difficulty of separating drug effects from accompanying psychotherapy, the need for prolonged patient observation by trained monitors, and questions around abuse potential and repeat dosing.

Enveric's EB-003 is designed to engage neuroplasticity-related receptor signaling associated with classic psychedelics while avoiding a hallucinogenic experience. The company said that if this profile is confirmed in clinical studies, EB-003 may be evaluated using conventional blinded trial designs and could support an outpatient treatment model.

"The agency is not lowering the standard. It is giving developers a clearer view of the issues that must be solved, including functional unblinding, patient monitoring, abuse potential, repeat dosing, and the role of psychotherapy. Those are exactly the types of issues that informed how we designed EB-003," said Joseph Tucker, Ph.D., CEO of Enveric.

The FDA guidance also encourages sponsors to engage early with the agency and supports the use of new approach methodologies and computer modeling based on chemical structure, molecular targets, and mechanism of action when evaluating safety and abuse potential.

Alongside the guidance, the FDA announced a Sept. 14, 2026, Part 15 public hearing on the potential future therapeutic use of psychedelic drugs in supervised settings. The hearing will address provider training, patient monitoring, reimbursement, access, and treatment-center capacity.

Enveric's planned Phase 1 clinical program for EB-003 is designed to assess safety, tolerability, pharmacokinetics, subjective effects, and pharmacodynamic biomarkers following single and repeat dosing. Subsequent studies would evaluate efficacy, durability of effect, and dosing requirements.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Rapid Line sees stock surge with no known corporate cause
• REPAY joins Visa Platform Connect to serve ISO and ISV clients